AB0666 The Survival of the anti Tumor Necrosis Factor Alpha in Patients with Ankylosing Spondylitis as First Line Treatment in Slovenian Nationwide Registry

Background Ankylosing spondylitis is potentially debilitating rheumatic disease. The introduction of biologics in treatment armamentarium made a radical change in prognosis. Anti tumor necrosis factor alpha (TNF-a) are the only biologics approved for treating NSAID resistant ankylosing spondylitis so far. That's why the survival of the drug is very important issue. Objectives To estimate the time of drug survival of first line anti TNF-a in patients with ankylosing spondylitis resistant to NSAIDs according to Slovenia nationwide registry (Biorx). Methods All the patients treated with biologics for rheumatic diseases in Slovenia are registered in nationwide registry. We included all patients treated with anti TNF-a agent as first line therapy between May 2010 and October 2013, namely adalimumab, golimumab, etanercept and infliximab. Results In observed period 377 patients (37,55% female patients, 80,92% HLA-B27 positive) with ankylosing spondilitis were treated with biologics, median age at baseline was 46, 6 years. Mean disease duration at baseline was 8,12 years. Survival rates in 180 weeks of treatment were 82%, 72%, 72% and 66% for adalimumab, etanercept, golimumab and infliximab, respectively. Conclusions Survival of first line therapy anti TNF a agent in ankylosing spondylitis is 76%. These results are in concordance with the previous published studies. References Braun J et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis Ann Rheum Dis 2011;70:896-904 Davis J e tal. Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis. Ann Rheum Dis. 2008 Mar;67(3):346-52 Glintborg B, Ostergaard M, Krogh NS, Dreyer L, Kristensen HL, Hetland ML: Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registry. Ann Rheum Dis 2010, 69:2002-2008. Seiper J et al. Tocilizumab (tcz) is not effecitve for the treatment f ankylosing spondlitis (AS): results of a phase 2, international, multicenre, randomised, double-blind, placebo-controlled trial.Ann Rheum Dis 2012;71(Suppl3):110 Glintborg B. et al. Clinical response, drug survival and predictors thereof in 432 patients with ankylosing spondilitis switching anti tumor necrosis factor alpha therapy. results from the Danish nationwide Danbio registry. Ann Rheum Dis. 2010 Nov;69(11):2002